Cell reports. Medicine

Wide vaccine protection against different global influenza A/H5Nx virus strains

Updated

Abstract

The digitally immune-optimized mRNA vaccine, DVX-panH5Nx, demonstrates superior protection against H5N1 challenges compared to traditional candidate vaccine viruses (CVVs).

  • DVX-panH5Nx was designed to include HA, NA, and M2 antigens from a wide range of circulating H5Nx viruses.
  • The vaccine shows broad hemagglutinin neutralization and neuraminidase inhibition in both mice and ferrets.
  • It is specifically optimized for N1 and N6 subtypes, which are associated with significant human health threats.
  • Compared to CVVs, DVX-panH5Nx provides enhanced protection against H5N1 strains that have evolved over the past two decades.
  • The findings indicate that computationally designed multivalent vaccines could effectively address challenges posed by influenza's natural variation.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free